Search Results - "Defer, Gilles"

Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring by Khoy, Kathy, Mariotte, Delphine, Defer, Gilles, Petit, Gautier, Toutirais, Olivier, Le Mauff, Brigitte

“…Multiple sclerosis is a chronic demyelinating disease of the central nervous system (CNS) with an autoimmune component. Among the recent disease-modifying…”
Get full text

Stroke and the immune system: from pathophysiology to new therapeutic strategies by Macrez, Richard, PhD, Ali, Carine, PhD, Toutirais, Olivier, PhD, Le Mauff, Brigitte, MD, Defer, Gilles, MD, Dirnagl, Ulrich, MD, Vivien, Denis, Prof

“…Summary Stroke is the second most common cause of death worldwide and a major cause of acquired disability in adults. Despite tremendous progress in…”
Get full text

Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients by Calocer, Floriane, Dejardin, Olivier, Droulon, Karine, Launoy, Guy, Defer, Gilles

“…In MS, Socio-Economic status (SES) may influence healthcare and access to disease-modifying treatments (DMTs). Optimising delays to switch patients to a…”
Get full text

Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence by Vivien, Denis, Gauberti, Maxime, Montagne, Axel, Defer, Gilles, Touzé, Emmanuel

“…About 15 million strokes occur each year worldwide. As the number one cause of morbidity and acquired disability, stroke is a major drain on public health-care…”
Get full text

Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis by Peyro Saint Paul, Laure, Debruyne, Danièle, Bernard, Delphine, Mock, Donald M, Defer, Gilles L

“…Multiple sclerosis (MS) is a chronic, potentially highly disabling neurological disorder. No disease-modifying treatments are approved in the progressive and…”
Get more information

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis by Branger, Pierre, Parienti, Jean-Jacques, Sormani, Maria Pia, Defer, Gilles

“…The quantification of brain atrophy in relapsing-remitting multiple sclerosis (RRMS) may serve as a marker of disease progression and treatment response. We…”
Get full text

Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis by Calocer, Floriane, Ng, Huah Shin, Zhu, Feng, Zhao, Yinshan, Dejardin, Olivier, Leray, Emmanuelle, Defer, Gilles, Evans, Charity, Fisk, John D, Marrie, Ruth Ann, Tremlett, Helen

“…Background: The relationship between socioeconomic status (SES) and mortality among persons with multiple sclerosis (PwMS) is poorly understood. Objective: To…”
Get full text

Prediction of disease activity in models of multiple sclerosis by molecular magnetic resonance imaging of P-selectin by Fournier, Antoine Philippe, Quenault, Aurélien, deLizarrondo, Sara Martinez, Gauberti, Maxime, Defer, Gilles, Vivien, Denis, Docagne, Fabian, Macrez, Richard

“…New strategies for detecting disease activity in multiple sclerosis are being investigated to ameliorate diagnosis and follow-up of patients. Today, although…”
Get full text

Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients by Ayrignac, Xavier, Carra-Dalliere, Clarisse, Menjot de Champfleur, Nicolas, Denier, Christian, Aubourg, Patrick, Bellesme, Celine, Castelnovo, Giovanni, Pelletier, Jean, Audoin, Bertrand, Kaphan, Elsa, de Seze, Jerome, Collongues, Nicolas, Blanc, Frederic, Chanson, Jean-Baptiste, Magnin, Eloi, Berger, Eric, Vukusic, Sandra, Durand-Dubief, Francoise, Camdessanche, Jean-Philippe, Cohen, Mickael, Lebrun-Frenay, Christine, Brassat, David, Clanet, Michel, Vermersch, Patrick, Zephir, Helene, Outteryck, Olivier, Wiertlewski, Sandrine, Laplaud, David-Axel, Ouallet, Jean-Christophe, Brochet, Bruno, Goizet, Cyril, Debouverie, Marc, Pittion, Sophie, Edan, Gilles, Deburghgraeve, Véronique, Le Page, Emmanuelle, Verny, Christophe, Amati-Bonneau, Patrizia, Bonneau, Dominique, Hannequin, Didier, Guyant-Maréchal, Lucie, Derache, Nathalie, Defer, Gilles Louis, Moreau, Thibault, Giroud, Maurice, Guennoc, Anne Marie, Clavelou, Pierre, Taithe, Frédérique, Mathis, Stephane, Neau, Jean-Philippe, Magy, Laurent, Devoize, Jean Louis, Bataillard, Marc, Masliah-Planchon, Julien, Dorboz, Imen, Tournier-Lasserve, Elisabeth, Levade, Thierry, Boespflug Tanguy, Odile, Labauge, Pierre

“…Inherited white matter diseases are rare and heterogeneous disorders usually encountered in infancy. Adult-onset forms are increasingly recognized. Our…”
Get full text

Relapses During High-Dose Biotin Treatment in Progressive Multiple Sclerosis: a Case-Crossover and Propensity Score-Adjusted Prospective Cohort by Branger, Pierre, Parienti, Jean-Jacques, Derache, Nathalie, Kassis, Nizam, Assouad, Rana, Maillart, Elisabeth, Defer, Gilles

“…High-dose biotin (HDB) is a therapy used in non-active progressive multiple sclerosis (PMS). Some reports have suggested that HDB treatment may be associated…”
Get full text

Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD) by Defer, Gilles-Louis, Widner, Hakan, Marié, Rose-Marie, Rémy, Philippe, Levivier, Marc

“…In 1992 the Core Assessment Program for Intracerebral Transplantations (CAPIT) was published providing the minimal requirements for a common patient evaluation…”
Get full text

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study by Leray, Emmanuelle, Vukusic, Sandra, Debouverie, Marc, Clanet, Michel, Brochet, Bruno, de Sèze, Jérôme, Zéphir, Hélène, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Clavelou, Pierre, Pelletier, Jean, Berger, Eric, Cabre, Philippe, Camdessanché, Jean-Philippe, Kalson-Ray, Shoshannah, Confavreux, Christian, Edan, Gilles

“…Recent studies in multiple sclerosis (MS) showed longer survival times from clinical onset than older hospital-based series. However estimated median time…”
Get full text

BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS by Cohen, Mikael, Mondot, Lydiane, Bucciarelli, Florence, Pignolet, Béatrice, Laplaud, David-Axel, Wiertlewski, Sandrine, Brochet, Bruno, Ruet, Aurélie, Defer, Gilles, Derache, Nathalie, Vermersch, Patrick, Zephir, Hélène, Debouverie, Marc, Mathey, Guillaume, Berger, Eric, Cappé, Chrystelle, Labauge, Pierre, Carra, Clarisse, De Seze, Jérôme, Bigaut, Kevin, Brassat, David, Lebrun-Frenay, Christine

“…Background: There are few head-to-head studies to compare highly active treatments in multiple sclerosis (MS) Objective: The aim of this study was to compare…”
Get full text

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study by Tourbah, Ayman, Gout, Olivier, Vighetto, Alain, Deburghgraeve, Véronique, Pelletier, Jean, Papeix, Caroline, Lebrun-Frenay, Christine, Labauge, Pierre, Brassat, David, Toosy, Ahmed, Laplaud, David-Axel, Outteryck, Olivier, Moreau, Thibault, Debouverie, Marc, Clavelou, Pierre, Heinzlef, Olivier, De Sèze, Jérôme, Defer, Gilles, Sedel, Frédéric, Arndt, Carl

“…Background Chronic visual loss is a disabling feature in patients with multiple sclerosis (MS). It was recently shown that MD1003 (high-dose…”
Get full text

Neuropsychological management of multiple sclerosis: evaluation of a supervised and customized cognitive rehabilitation program for self-used at home (SEPIA): protocol for a randomized controlled trial by Harand, Caroline, Daniel, France, Mondou, Audrey, Chevanne, Damien, Creveuil, Christian, Defer, Gilles

“…Cognitive and mood disorders negatively impact daily life in patients with multiple sclerosis (MS). Pharmacological treatments did not demonstrate any effect…”
Get full text

Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis by Clavelou, Pierre, Castelnovo, Giovanni, Pourcher, Valérie, De Sèze, Jerome, Vermersch, Patrick, Ben-Amor, Ali-Frederic, Savarin, Carine, Defer, Gilles

Get full text

Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis by Clavelou, Pierre, Castelnovo, Giovanni, Pourcher, Valérie, De Sèze, Jerome, Vermersch, Patrick, Ben-Amor, Ali-Frederic, Savarin, Carine, Defer, Gilles

“…Cladribine tablets (CladT) is a highly active oral disease-modifying therapy (DMT) for the management of relapsing multiple sclerosis (RMS). CladT acts as an…”
Get full text

Accuracy and cutoff values of delayed heart to mediastinum ratio with (123)I-metaiodobenzylguanidine cardiac scintigraphy for Lewy body disease diagnoses by Lamotte, Guillaume, Morello, Rémy, Lebasnier, Adrien, Agostini, Denis, Defer, Gilles L

“…Different studies have found diminished cardiac metaiodobenzylguanidine (MIBG) uptake in Lewy body (LB) related conditions (Parkinson's disease (PD) and Lewy…”
Get full text

Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial by Defer, Gilles, Le Caignec, Florian, Fedrizzi, Sophie, Montastruc, François, Chevanne, Damien, Parienti, Jean-Jacques, Peyro-Saint-Paul, Laure

“…The reporting of adverse drug reactions (ADR) by patients represents an interesting challenge in the field of pharmacovigilance, but the reporting system is…”
Get full text

Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis by Mathais, Sophie, Moisset, Xavier, Pereira, Bruno, Taithe, Frédéric, Ciron, Jonathan, Labauge, Pierre, Dulau, Cécile, Laplaud, David, De Seze, Jérôme, Pelletier, Jean, Berger, Eric, Lebrun-Frenay, Christine, Castelnovo, Giovanni, Edan, Gilles, Defer, Gilles, Vermersch, Patrick, Bourre, Bertrand, Camdessanche, Jean-Philippe, Magy, Laurent, Guennoc, Anne-Marie, Mathey, Guillaume, Moreau, Thibault, Gout, Olivier, Heinzlef, Olivier, Maillart, Elisabeth, Vukusic, Sandra, Clavelou, Pierre

“…High-dose biotin (HDB) is a therapy used in non-active progressive multiple sclerosis (PMS). Several reports have suggested that HDB treatment may be…”
Get full text